Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

July was a landmark month for nephrology, headlined by a wave of 

and a first-ever regulatory pathway forming for primary membranous nephropathy (pMN).

Within the span of 3 weeks, the FDA granted accelerated approval to a new dual BAFF/APRIL inhibitor, converted a complement inhibitor's accelerated approval to full approval based on 2-year kidney function data, and cleared a needle-free, at-home diuretic option for fluid overload in heart failure (HF) and 

. Genentech's obinutuzumab also moved a step closer to becoming the first FDA-approved therapy for pMN, while new data from the VISIONARY and FIND-CKD trials expanded the evidence base for sibeprenlimab and finerenone, respectively.

Rounding out the month, new research quantified a persistent access gap in kidney transplant evaluation, and a panel of nephrology experts weighed in on how SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists have reshaped CKD management heading into the second half of 2026.

Below, HCPLive rounds up the 8 nephrology stories that had the biggest clinical and regulatory impact in July 2026, from FDA approvals and priority reviews to new trial data and expert perspective on where CKD care stands today.

FDA Approves Atacicept (Trutakna) for IgA Nephropathy

On July 7, 2026, the FDA granted accelerated approval to atacicept-vymj (Trutakna), a dual BAFF/APRIL inhibitor, to reduce proteinuria in adults with primary IgAN at risk of disease progression. The decision was supported by a prespecified interim analysis of the phase 3 ORIGIN 3 trial, in which atacicept produced a statistically significant 42% reduction in proteinuria versus placebo at 36 weeks. The once-weekly subcutaneous injection is self-administered via autoinjector.

FDA Grants Obinutuzumab Priority Review as Primary Membranous Nephropathy's Potential First Therapy

On July 14, 2026, the FDA granted priority review to Genentech's supplemental biologics license application for obinutuzumab (Gazyva) in primary membranous nephropathy, based on phase 3 MAJESTY data showing 36.9% of patients achieved complete remission at 2 years versus 5.7% with tacrolimus. A decision is expected by November 2026; if approved, obinutuzumab would be the first FDA-approved therapy for this chronic autoimmune kidney disease.

FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN

On July 17, 2026, Novartis' iptacopan (Fabhalta) converted from accelerated to traditional FDA approval to slow kidney function decline in adults with primary IgAN at risk of progression. The upgrade was backed by 2-year data from the phase 3 APPLAUSE-IgAN trial, which met its final primary endpoint and demonstrated significantly slower eGFR decline with iptacopan versus placebo, making it the first complement inhibitor to show this durability of benefit in IgAN.

FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD

On July 24, 2026, the FDA approved MannKind's Furoscix ReadyFlow, the first and only autoinjector delivering subcutaneous furosemide with IV-equivalent exposure, cutting administration time from 5 hours (with the existing on-body infusor) to under 10 seconds. The at-home option is approved for edema in adults with HF or CKD and is expected to be commercially available by the end of August 2026.

Interim Phase 3 VISIONARY Data Show Sibeprenlimab Preserved Kidney Function in IgA Nephropathy

Interim findings from the phase 3 VISIONARY trial showed that sibeprenlimab preserved kidney function over 12 months in adults with IgAN, adding to the growing body of evidence for APRIL-targeted therapies in this progressive disease.

FIND-CKD Expands Finerenone Evidence Beyond Diabetic CKD, With Rajiv Agarwal, MD

In this interview, Rajiv Agarwal, MD, MS, discusses new phase 3 FIND-CKD results demonstrating reduced eGFR decline with finerenone in patients with nondiabetic CKD—a population representing more than half of all CKD cases. The conversation covers how these findings extend finerenone's evidence base well beyond its original diabetic kidney disease indication and what that could mean for broader use of the nonsteroidal mineralocorticoid receptor antagonist in clinical practice.

Why Fewer Than Half of Referred Patients Reach Kidney Transplant Evaluation

New research found that nearly half of kidney transplant candidates referred for evaluation never actually start the process, with access barriers varying significantly by patient background, underscoring a persistent gap between referral and actual transplant workup.

Where Are We Now? Treating Chronic Kidney Disease in 2026

Experts discuss how CKD management has evolved through 2026, covering the maturing roles of SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, and how clinicians are increasingly personalizing treatment as the drug landscape expands.

Articles

July 2026 delivered multiple inflection points in kidney disease therapeutics, especially in IgA nephropathy, with new accelerated approval for dual BAFF/APRIL inhibition and full approval for complement inhibition supported by 2-year eGFR data. Regulatory momentum also advanced primary membranous nephropathy toward a first approved therapy via priority review for obinutuzumab. Practice-facing innovation included an ultra-rapid, at-home subcutaneous furosemide autoinjector for edema in HF/CKD. New trials broadened evidence for APRIL targeting and finerenone in nondiabetic CKD, alongside renewed focus on transplant-access gaps and evolving multidrug CKD strategies.

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

FDA News

8 Nephrology Headlines You Missed in July 2026

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

July 2026 was relatively quiet for endocrinology. The 

 had no significant approvals, instead accepting 2 exciting New Drug Applications (NDAs) for the treatment of hypocalcemia and 

, respectively. Additionally, key trials for 

 following GLP-1 RA discontinuation had topline results read out over the course of the month, moving major candidates like encaleret and tegoprubart further down the treatment pipeline towards an FDA decision.

 editorial team has collected 5 of the most impactful headlines from the past 31 days below. As we move into the final month of summer, catch up on some of the news you might’ve missed in July this year:


FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1


On July 22, 2026, the FDA accepted an NDA for encaleret for autosomal dominant hypocalcemia type 1 (ADH1). Announced by parent company BridgeBio, this decision positions the orally administered small molecule, designed to selectively negatively modulate the calcium sensing receptor, to become the first and only therapy specifically indicated for patients with ADH1. Encaleret has been assigned a Prescription Drug User Fee Act (PDUFA) date of May 8, 2027.


FDA Accepts Resubmitted CAM2029 NDA for Acromegaly


On July 16, 2026, the FDA announced its acceptance of a resubmitted NDA for CAM2029, an investigative, once-monthly subcutaneous octreotide depot, for patients with acromegaly. This follows a complete response letter (CRL) issued on June 10, 2026, which cited observations from a current good manufacturing practice inspection of a third-party manufacturer. However, no safety or efficacy concerns were identified in the letter, according to parent company Camurus. CAM2029 has been assigned a PDUFA date of December 18, 2026.


Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials


Following a banner month in June, retatrutide has successfully met the primary weight loss endpoints in the TRIUMPH-2 and TRIUMPH-3 trials, which included patients with T2D and obesity or overweight and patients with a BMI ≥35 and established cardiovascular disease. In addition to these topline results, parent company Eli Lilly has also announced its intention to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027, following completion of its chemistry, manufacturing, and controls package.


REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System


New 1-year data from the REMAIN-1 Midpoint Cohort, announced by parent company Fractyl Health on July 15, 2026, have shown the potential of the Revita Duodenal Mucosal Resurfacing (DMR) System as the first durable procedural therapy for weight maintenance after discontinuing GLP-1 RA treatment. The procedure demonstrated successful weight reduction compared to sham, with no serious adverse events related to either the procedure or the device. Fractyl Health expects to receive topline data from the REMAIN-1 Pivotal Cohort in early Q4 2026.


All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study


Eledon’s investigator-initiated trial of islet cell transplantation for T1D saw its 12th and final patient discontinued from external insulin following transplant and treatment with tegoprubart. The humanized monoclonal antibody selectively inhibits CD40 ligand, which is involved in the activation of T cells. In addition to demonstrating effective treatment with optimal tolerability in islet cell transplantation, tegoprubart is also being investigated in xenotransplantation, liver and kidney allograft transplantation, and amyotrophic lateral sclerosis.

July 2026 endocrinology updates centered on regulatory progress and pivotal readouts rather than new FDA approvals. The FDA accepted an NDA for encaleret in autosomal dominant hypocalcemia type 1, with a May 8, 2027 PDUFA date, and accepted a resubmitted NDA for once-monthly octreotide depot CAM2029 in acromegaly, with a December 18, 2026 PDUFA date after a manufacturing-focused CRL. Retatrutide met Phase 3 weight-loss endpoints; Revita DMR supported post–GLP-1 weight maintenance; and tegoprubart-enabled islet transplantation achieved insulin independence in all 12 recipients.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Hormonal Disorders

5 Endocrinology Headlines You Missed in July 2026

 (EPP) remains among dermatology's most under-recognized diagnoses, often mistaken for solar urticaria or polymorphic light eruption for years before clinicians identify its hallmark feature: severe burning pain after sun exposure with little or no visible skin change.

, hosts Lindsay Ackerman, MD, and Christopher Bunick, MD, PhD, spoke with Angelika Erwin, MD, PhD, founder and director of the Porphyria Center at Cleveland Clinic, about diagnosing and managing EPP and its X-linked counterpart, XLP.

On this episode of ABCs in Dermatology, Angelika Erwin, MD, PhD, founder and director of the Porphyria Center at Cleveland Clinic, joins hosts Lindsay Ackerman, MD, and Christopher Bunick, MD, PhD, to discuss a rare, often-missed photosensitivity disorder and how care for it is evolving.

ABCs in Dermatology: Updates in Erythropoietic Protoporphyria Management for 2026

EPP results from ferrochelatase deficiency, causing free protoporphyrin IX to accumulate in red blood cells, plasma, and skin. Pain typically strikes within minutes of sun exposure, most often on the backs of the hands, and can precede any visible finding. Onset usually occurs between ages 1 and 4, and diagnosis is frequently delayed for years because symptoms resolve before a clinician examines the skin. About 5% of patients develop protoporphyric hepatopathy, which in rare cases progresses to fulminant liver failure requiring transplantation paired with bone marrow transplant, since liver transplant alone is not curative.

Erwin outlined a diagnostic pathway starting with plasma total porphyrins, available through standard commercial labs, followed by erythrocyte protoporphyrin testing at specialized centers such as Mayo Clinic or ARUP to distinguish EPP from XLP based on the ratio of free to zinc-bound protoporphyrin. Urine porphyrins remain normal in both conditions and should not be used for screening. Genetic testing targets the FECH gene in EPP, an autosomal recessive condition typically involving a common low-expression allele paired with a disease-causing mutation, and the ALAS2 gene on the X chromosome in XLP.

Before afamelanotide's 2019 approval, management relied on physical sun avoidance, zinc oxide and titanium dioxide sunscreens, and UV-filtering window films, with limited benefit from oral beta-carotene. Afamelanotide, a subcutaneous implant given every 60 days, increased pain-free sun exposure by a mean of 69 hours over 6 months versus placebo in the US phase 3 trial

, though it is not approved in pediatric patients. Bitopertin, an oral glycine transporter 1 inhibitor now in phase 3 testing, reduces porphyrin production upstream in the heme biosynthetic pathway and has shown promise in patients as young as 12 years in earlier trials

Erwin also pointed to earlier-stage candidates, including an ABCG2 inhibitor, ex vivo FECH gene replacement, mRNA-based delivery, and dersimelagon, an oral melanocortin receptor agonist in phase 3 testing. She emphasized that suspected EPP warrants erythrocyte protoporphyrin or plasma porphyrin testing rather than urine studies, and that confirmed cases require coordinated monitoring of liver function and vitamin D levels alongside referral to a specialized porphyria center.

Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. doi:

Yeung AK, Bonkovsky HL, Balwani M, et al. Bitopertin shows efficacy in patients with erythropoietic protoporphyria: results from the randomized, double-blind, placebo-controlled AURORA trial. J Am Acad Dermatol. 2025. doi:

Erythropoietic protoporphyria and X-linked protoporphyria present in early childhood with rapid-onset, severe phototoxic burning pain and minimal visible erythema, leading to frequent misdiagnosis and prolonged diagnostic delay. Pathobiology centers on excess protoporphyrin IX from ferrochelatase deficiency (EPP) or ALAS2 gain-of-function (XLP), with rare but serious protoporphyric hepatopathy. Diagnosis hinges on plasma porphyrins and specialized erythrocyte protoporphyrin fractionation, not urine testing. Management has shifted from strict photoprotection to melanocortin-based and heme-pathway–targeted therapies.

Angelika Erwin, MD, PhD, joins the podcast to discuss diagnosing and managing EPP and XLP on ABCs in Dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

The STOP-HS1 and STOP-HS2 trials mark the first phase 3 publication of an oral therapy for hidradenitis suppurativa.

Povorcitinib's JAK1-selective mechanism differs from existing biologic options like TNF-alpha and IL-17 inhibitors.

The oral option may benefit patients hesitant about injections or those who haven't responded to biologic therapy.

 remains one of dermatology's most challenging skin conditions to address, according to Martina Porter, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School.

Porter discussed new peer-reviewed phase 3 STOP-HS1 and STOP-HS2 results evaluating povorcitinib in adult patients living with moderate-to-severe HS, recently published in 

 interview about the treatment, about HS, and about the unique aspects of these new data.

Why Povorcitinib's JAK1 Mechanism Matters for HS (Hidradenitis Suppurativa), With Martina Porter, MD

Why Povorcitinib's JAK1 Mechanism Matters for HS, With Martina Porter, MD

Why Is Hidradenitis Suppurativa So Difficult to Treat?

Porter described HS as having historically lagged behind conditions like psoriasis and atopic dermatitis in treatment availability and efficacy. She emphasized the disease carries a significant psychosocial burden, with high rates of depression, anxiety, and suicidality, along with unpredictable flares that can affect patients' ability to work, dress, and maintain relationships.

What Makes Povorcitinib and the STOP-HS Trials Significant?

Porter explained the STOP-HS1 and STOP-HS2 trials represent the first phase 3 publication of an oral therapy for HS. Until now, all FDA-approved options for moderate-to-severe disease, including adalimumab, secukinumab, and bimekizumab, have been biologics requiring injection.

Povorcitinib, a selective JAK1 inhibitor, offers both a new mechanism and a needle-free option, which Porter said may appeal particularly to younger patients or those hesitant about injectable therapies. She also pointed to the flexibility of starting and stopping oral treatment as a meaningful factor in shared decision-making conversations with patients.

How Does Povorcitinib's Mechanism Differ From Existing HS Drugs?

Porter described povorcitinib as a highly selective JAK1 inhibitor, distinguishing it from JAK2- and JAK3-mediated pathways associated with hematopoiesis-related side effects. She noted that HS is likely a heterogeneous disease without a single unifying driver, meaning treatment response may vary considerably across patients.

Because JAK1 inhibition operates through a broader pathway than TNF-alpha or IL-17 inhibition, Porter suggested it may offer an alternative for patients who have not responded to existing biologic therapies, particularly those with early nodular disease or more severe, tunneling-type presentations.

Disclosures: Porter has served as a consultant for AbbVie, Almirall, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Eli Lilly, Framework for Interoperable Data Exchange (FIDE), Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, Trifecta Clinical/WCG, UCB and Zura Bio and as an investigator for AbbVie, AnaptysBio, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Bayer, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, OASIS Pharmaceuticals, Otsuka, Pfizer, Prometheus, Propeller Biosciences, Regeneron, Sanofi, Sonoma Biotherapeutics, UCB and Zura Bio. She has received royalties from Beth Israel Deaconess Medical Center and fellowship funding to the institution from AbbVie.

Porter ML, Martorell A, Zouboulis CC, et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat Med. 2026 Jul 23. doi: 10.1038/s41591-026-04534-z. Epub ahead of print. PMID: 42493571.

Porter M. Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD. HCPLive. April 1, 2026. Accessed August 3, 2026. 

https://www.hcplive.com/view/povorcitinib-delivers-deepening-responses-through-54-weeks-moderate-to-severe-hs-porter

Videos

Martina Porter, MD, discusses new STOP-HS trial data on povorcitinib, the first oral phase 3 therapy for hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

In "Defining On-Treatment Remission in Psoriasis and PsA," the panel examines whether clear should now mean completely clear.

Defining On-Treatment Remission in Psoriasis and PsA

Dr. Han recounts his work with the National Psoriasis Foundation and its earlier treat-to-target guidelines. Some clinicians resisted them, and he was initially skeptical too. But he came to see the point. With so many effective medicines, the commitment behind systemic treatment is to let patients live a normal life without thinking about psoriasis.

Dr. Han explains the reasoning behind the target. The minimal response worth having on a measure like PASI is around 50%, which is a low bar, and 50% clear is happier but still not where a patient can be. Because current therapies can do far more, he argues clinicians should hold themselves to a higher standard. A cure does not exist yet, so full remission off treatment is not attainable. What is attainable is on-treatment remission: no psoriasis on the body, defined as 0% BSA, PASI 100, or IGA 0.

Dr. Han concedes there is no equivalent on the psoriatic arthritis side, describing patients who bounce between improving joints and flaring skin as therapies get layered on, sometimes back to a TNF. Dr. Wright agrees the field has only nudged from ACR20 to ACR50. She stresses that rheumatology must think across domains, so clear joints with active skin is not remission.

Dr. Wright introduces minimal disease activity, framed as her rule of zeros and ones across enthesitis, dactylitis, and other measures. She notes that MDA requires 5 of 7 criteria, while the stricter VLDA requires all 7. She also flags the harder problem: patients whose joints stay painful despite clear skin, forcing a distinction between residual inflammation and truly treatment-refractory disease.

The next episode in this series, "Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis," opens the second section as Dr. Wright walks through the key biologic pathways that drive psoriatic disease.

Video Series

"Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care" takes up the question of how two specialties can stop working in isolation.

Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Catch up on July dermatology news: vitiligo and alopecia data, a pipeline discontinuation, psoriasis comparisons, and an FDA sNDA acceptance.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

7 Dermatology Headlines You Missed in July 2026

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

6 Allergy Headlines You Missed in July 2026

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Structural Heart Disease

6 Cardiology Headlines You Missed in July 2026

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What EASI 75, vIGA-AD Scores Reveal About Tapinarof's Eczema Efficacy

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Planetary Health Diet Reduces Risk of Cardiovascular Disease, CHD, Stroke, HF

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Pooled FIBRONEER trial data show nerandomilast reduced the risk of death by up to 43% versus placebo, though the analysis was post hoc.

Pulmonary Fibrosis

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Nerandomilast Reduces Mortality Risk in Pulmonary Fibrosis Analysis

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Pranav Garimella, MD, on how nephrologists and cardiologists can apply GLP-1 receptor agonist evidence to CKD treatment decisions.

GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy

Trace how oral plaque psoriasis therapy has evolved over time, from PDE4 and TYK2 inhibition to once-daily oral peptides.

Latest News

8 Nephrology Headlines You Missed in July 2026

5 Endocrinology Headlines You Missed in July 2026

ABCs in Dermatology: Updates in Erythropoietic Protoporphyria Management for 2026

Why Povorcitinib's JAK1 Mechanism Matters for HS, With Martina Porter, MD

Defining On-Treatment Remission in Psoriasis and PsA